Integral Derivatives’s Tempest Therapeutics TPST Stock Holding History

Integral Derivatives’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-19	Closed	-$86K	–	1370
2016 Q4	$86K	Buy	+19	New	+$237K	﹤0.01%	1071

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Integral Derivatives's TPST Position: Q1 2017 in Review

Integral Derivatives sold out of Tempest Therapeutics (TPST) in Q1 2017, closing a stake of 19 shares — an estimated $86K sold.

Integral Derivatives first reported a position in TPST in Q4 2016 and held it in 1 quarter. The position peaked at $86K in Q4 2016. 63 funds tracked by Wall St. Rank hold TPST as of Q1 2017.

Integral Derivatives reported no remaining Tempest Therapeutics position as of Q1 2017 after selling out during the quarter.
Integral Derivatives sold 19 Tempest Therapeutics shares in Q1 2017, an estimated $86K.
Integral Derivatives first reported a position in Tempest Therapeutics in Q4 2016 and held it in 1 quarter.
Integral Derivatives's Tempest Therapeutics position peaked at $86K in Q4 2016.
63 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2017.

Based on Integral Derivatives's 13F filing for Q1 2017, filed 15 May 2017.